Gastrointestinal stromal tumor (GIST) is the most common soft tissue sarcoma of the gastrointestinal tract and, in the vast majority of cases, is characterized by activating mutations in KIT or, less commonly, PDGFRA. Mutations in these type III receptor tyrosine kinases (RTKs) account for over 85% of GIST cases, and the majority of KIT primary mutations respond to treatment with the tyrosine kinase inhibitor (TKI) imatinib. However, drug resistance develops over time, most commonly due to secondary kinase mutations. Sunitinib and regorafenib are approved for the treatment of imatinib-resistant GIST in the second and third lines, respectively. However, resistance to these agents also develops and new therapeutic options are needed. In addition, a small number of GISTs harbor primary activating mutations that are resistant to currently available TKIs, highlighting an additional unmet medical need. Several novel and selective TKIs that overcome known mechanisms of resistance in GIST have been developed and show promise in early clinical trials. Additional emerging targeted therapies in GIST include modulation of cellular signaling pathways downstream of KIT, antibodies targeting KIT and PDGFRA and immune checkpoint inhibitors. These advancements highlight the rapid evolution in the understanding of this malignancy and provide perspective on the encouraging horizon of current and forthcoming therapeutic strategies for GIST.
Introduction
Gastrointestinal stromal tumor (GIST) is among the most common soft tissue sarcomas, with an estimated annual incidence of up to 6000 cases in the USA [1] , and population-based annual incidence rates of 0.78-1.1 cases per 100 000 [2, 3] . Their recognition as a pathologic entity distinct from smooth muscle and other gastrointestinal mesenchymal tumors came first from the identification of specific immunohistochemical markers, and subsequently the discovery of recurrent activating mutation in the type III receptor tyrosine kinases (RTKs) KIT and PDGFRA [4] [5] [6] [7] . Due to similar morphologic and expression patterns, GIST has been hypothesized to arise from the transformation of interstitial cells of Cajal [8] or their cellular progenitors, which are pacemaker cells situated between enteric neurons and the smooth muscle of the gastrointestinal tract that regulate gut motility.
KIT is normally expressed in many tissues during development and is important for hematopoiesis, gut motility, gametogenesis, neurodevelopment, pigmentation, mast cell function and vascular endothelial formation [9] . Wild-type KIT is activated upon binding its ligand, stem cell factor (SCF), which induces receptor dimerization and subsequent conformational changes. These structural changes evict the inhibitory juxtamembrane (JM) domain from the split kinase domains. Activation of the kinase domains requires a conformational change in the activation loop (A-loop), enabling the kinase domains to bind ATP and phosphorylate target substrates. Phosphorylation of the KIT intracellular domain constructs docking sites for several mediators of signal transduction, stimulating signaling through the Ras/MAP kinase pathway, the JAK/STAT pathway, PLC/PKC and the PI3K/ AKT/mTOR pathway ( Figure 1A and B) [9] .
Activating mutations in several domains within KIT and PDGFRA lead to dysregulated receptor signaling (Figures 1C and 2) . Crystal structures of the KIT extracellular and kinase domains have shed light into how these mutations lead to aberrant receptor activity. Mutations in exon 9, which encodes the C-terminal portion of the ectodomain including the immunoglobulin-like D5 domain, lead to aberrant receptor activation through ligand-independent dimerization ( Figure 2A ) [12, 18] . Exon 11 encodes the JM domain of KIT, which stabilizes the autoinhibited kinase conformation with the A-loop in the 'DFG-Out' orientation ('DFG' indicates the first three amino acids of the A-loop: aspartate, phenylalanine and glycine) which sterically blocks the ATP-binding pocket ( Figure 2B ) [14] . Deletions, insertions or mutation of the JM domain produces a disinhibited and unregulated kinase domain, and represents the most common KIT activating mutation in GIST [19] . Mutation in exon 13, encoding the tyrosine kinase 1 (TK1) domain, and exon 17, encoding the TK2 domain, are rare in primary GIST tumors [20] . Mutations in exon 13 alter areas of TK1 important for contact with the JM domain and also with the ATP-binding-pocket and imatinib [21] . Exon 17 and 18 mutations lie within the A-loop, biasing the A-loop toward the 'DFG-in' conformation that excludes the inhibitory JM domain and permits ATP and substrate binding ( Figure 2C and D) [10] . These structural insights into aberrant receptor activation in KIT and related tyrosine kinases has led to an understanding of drug resistance and significant advances in the development of kinase inhibitors which can bind to the active (type I inhibitors) or inactive (type II inhibitors) kinase states and other mechanisms of kinase inhibition [22] . As these mechanistic insights have evolved into novel therapeutic approaches currently being deployed, an appreciation of their therapeutic basis is important for modern oncology clinical practice.
In addition to GIST, activating KIT mutations have also been implicated in mastocytosis, seminoma, natural killer/T-cell lymphomas, acute myeloid leukemia, thymic carcinoma, melanoma and myeloproliferative disorders [23] . Germline activating KIT mutations are rare, with reported mutations involving exons 8, 9, 10, 11, 13 and 17. Affected individuals have variable phenotypes, with hyperpigmentation, gastrointestinal motility disorders and increased risk of cancers limited to GIST and mastocytosis [24] . Germline PDGFRA mutations resulting in familial GIST have also been reported [25] .
Recently, the discovery of circulating tumor DNA has arisen as a method to detect, monitor response to therapy and identify resistance mutations in several cancer subtypes [26] . This methodology has been applied to GIST in the research setting and shown preliminary utility in diagnosis before tumor biopsy [27] , in monitoring response to therapy [28] and in identifying tyrosine kinase inhibitor (TKI) resistance mutations [29] .
Though not yet formally part of the standard diagnostic armamentarium, this approach is currently being evaluated in clinical trials as a surrogate marker for disease control and evolution of drug resistance mutations, with early results suggesting circulating tumor DNA may be a more sensitive and rapid indicator of disease response compared with imaging [30] . 
Current therapy
Before targeted therapy, effective treatment options for GIST were limited to surgical resection, when feasible. Five-year survival for all patients diagnosed with GIST was 35%, and in those with metastatic disease at presentation or disease recurrence median survival was 12-19 months [31] . Shortly after the identification of activating KIT mutations in GIST, imatinib was found to selectively inhibit KIT signaling in vitro [32] and effectively treat metastatic tumors in patients with GIST [33] . In contrast to the prior dismal outlook for patients with metastatic or unresectable GIST, treatment with imatinib significantly prolongs survival, with approximately half of patients with metastatic disease surviving beyond 5 years [34] . Imatinib achieves disease control (in the form of complete or partial responses or stable disease) in 80% of advanced KIT-expressing GIST, with median progression-free survival of 20-24 months [35] and 5-year overall survival of 69% in primary exon 11 mutant GIST, 49% in exon 9 mutant GIST and 40% in wild-type GIST treated with 400 mg imatinib [36] . Exon 9 mutant tumors have a higher response rate when treated at 800 mg imatinib daily [37] . Approximately In (E) and (F), activating mutation sites seen in GIST and the associated native amino acid side-chains are highlighted in purple. The most common A-loop mutation is labeled in both KIT and PDGFRA structures. (G) Expanded view of the KIT kinase domain with color-coded structures including ATP, imatinib, sunitinib [10] , ponatinib [16] and PLX647 [17] that were merged on to sunitinib-bound KIT to obtain relative positions of each molecule. Structures were modified with UCSF Chimera software (http://www.rbvi.ucsf.edu/chimera).
one-fourth of patients experience prolonged disease control on imatinib and subsequent lines of therapy [38] . The success of imatinib used in the metastatic setting has also led to interest in its use as a neoadjuvant and adjuvant therapy. Neoadjuvant imatinib is deployed with the goal of reducing operative morbidity, with treatment having demonstrated safety, efficacy in tumor size reduction and enabling less morbid surgery [39, 40] . For completely resected GIST tumors treated without neoadjuvant imatinib, select tumors at high risk of recurrence [41] may benefit from adjuvant imatinib [42] . For these high-risk patients, adjuvant imatinib has been shown to improve recurrence-free and overall survival, with 3 years of therapy being superior to one [43] . Importantly, treatment with adjuvant imatinib may not promote the development of imatinib-resistance mutations in patients with recurrent disease [44] . The benefit of longer durations of adjuvant treatment with imatinib is currently under investigation. In early reports, the single-arm PERSIST-5 trial (NCT00867113) is evaluating 5 years of adjuvant imatinib in GIST patients at high risk of recurrence. In this study, nearly half of patients discontinued imatinib early, and while most recurrences occurred following imatinib cessation, the single patient who recurred on adjuvant therapy had a PDGFRA D842V mutation [45] . Two additional trials underway (NCT02260505 and NCT02413736) are comparing 3 to up to 6 years of adjuvant imatinib. There may be additional opportunity to more accurately risk-stratify patients through molecular features of the tumor, both from the specific RTK mutation [46] as well as from an emerging understanding of GIST biology predictive of metastatic behavior [47] .
Resistance to imatinib therapy occurs in the majority of patients, with risk increasing over time on therapy, and is commonly due to KIT mutations that render the kinase domain resistant to inhibitor therapy [48] . For progressing tumors with primary exon 11 mutations, the secondary kinase domain mutation evolves at a median of 27 months, which suggests either the generation of a secondary KIT mutation or competitive growth of a pre-existing but rare drug-resistant clone, although studies remain ongoing in this arena [49] . These secondary mutations commonly lie within either the ATP-binding pocket or A-loop domains in KIT and PDGFRA, biasing the kinase domain toward the active state and excluding the binding of standard TKIs (Figure 2E-G) .
Amplification of KIT is not a common mechanism of disease progression or drug resistance [49, 50] , although hemizygous KIT mutations following loss of the wild-type allele have been correlated with more aggressive disease [51] . Under effective treatment with KIT inhibition, tumor volume decreases as GIST cells undergo apoptosis and cell cycle arrest following withdrawal of trophic kinase signaling [52] . However, even following effective long-term treatment with TKIs, GIST tumor cells can remain viable but quiescent and may escape cell death through alterations in gene expression, transdifferentiation and autophagy [53, 54] . It remains incompletely understood how this subpopulation of tumor cells survives years of TKI therapy and later emerges with treatment resistant RTK mutations, and how this process can be therapeutically interrupted.
Following resistance to imatinib, subsequent lines of TKIs associated with more modest rates and durations of disease control have been developed. Second-line therapy with sunitinib has been found to prolong time to progression compared with placebo from 6.4 to 27.3 weeks [55] . Third-line therapy with regorafenib similarly prolongs progression-free survival from 0.9 to 4.8 months compared with placebo [56] . Compared with firstline imatinib, the more modest benefits conferred by these second-and third-line TKIs likely arises from the emergence of multiple unique drug-resistant KIT mutations within an individual tumor [49, 57] . Despite heterogeneity at the time of imatinib resistance, secondary KIT mutations occur in a nonrandom pattern, with mutations clustered in both the ATP binding pocket and the A-loop.
Other TKIs have been evaluated for advanced GIST, including pazopanib [58] , ponatinib [16] , sorafenib [59] and nilotinib [60] , though results have been less supportive of their clinical development in imatinib-resistant GIST. Additional multi-targeted TKIs approved for the treatment of other malignancies are currently under clinical evaluation in imatinib-resistant GIST (e.g. NCT02216578), which may offer additional lines of therapy for this disease. All of these TKIs have overlapping contact sites within the ATP-binding pocket of KIT ( Figure 2G ), and their unique points of contact dictate the KIT mutations they are able to inhibit as well as their kinase selectivity and promiscuity.
PDGFRA-mutant GIST bears alterations in analogous functional domains of this related type III RTK, though the preponderance of PDGFRA activating mutations lie within the A-loop. Compared with KIT-mutant tumors, PDGFRA mutant tumors primarily have a gastric origin [61] , epithelioid morphology [62] and appear to be less adept at metastasis [63] [64] [65] . Many PDGFRA mutations are sensitive to imatinib in the first-line setting, with the notable exceptions including the D842V mutation that is highly resistant to currently approved TKIs. The D842V mutation is the most common PDGFRA mutation and represents a clear unmet medical need [66] . KIT and PDGFRA mutations are mutually exclusive and drive a similar repertoire of signal transduction pathways [7] . Other less common oncogenic causes of GIST, making up less than 10% of total cases, include NF1 loss of function mutations [67] , SDH deficiency [68] , BRAF mutation [69] and NTRK or FGFR1 fusions [70, 71] .
Novel tyrosine kinase inhibitors
Akin to other RTK-dependent malignancies, GIST can remain reliant upon kinase signaling even following years of effective treatment with TKIs [72, 73] . The liabilities of currently available TKIs are the development of secondary resistance mutations, which modify the structure of the kinase domain to prevent therapeutic KIT inhibition [74] . In imatinib-resistant GIST, sunitinib has been found to be most effective in vitro and in clinical experience at targeting secondary mutations involving the ATPbinding pocket encoded by exons 13 and 14 [75] . Evaluation of tissue biopsies following imatinib failure demonstrates the V654A ATP-binding pocket mutation as the most common site of imatinib resistance [76] . In contrast, in a phase II trial of regorafenib in GIST following failure of imatinib and sunitinib, preand postregorafenib treatment biopsies demonstrated inhibition of KIT protein phosphorylation in GIST tumors with A-loop mutations, primarily in exon 17 [77] . Though kinases other than KIT are inhibited by these TKIs and may contribute to their clinical efficacy, these data suggest that later line inhibitors target a selective range of imatinib resistance mutations. The ability to pharmacologically target a spectrum of kinase-domain mutations has generated enthusiasm for the development of additional lines of TKIs, with specific inhibition of common resistance mutations in KIT and PDGFRA, several of which are currently under active clinical investigation.
Crenolanib is a novel inhibitor of type III RTKs in development for PDGFRA D842V mutant GIST, among other malignancies. It has been shown to potently and selectively inhibit many PDGFRA mutations found in GIST [78] , and is currently in a phase III trial for PDGFRA D842V mutant GIST (NCT02847429). Early results from a phase II trial have been presented in preliminary form and suggest possible clinical activity. However, the spectrum of kinase inhibition is broad and suggests multiple targets in addition to PDGFRA [79] .
Imatinib, sunitinib and regorafenib are type II kinase inhibitors, and as such preferentially bind to the inactive kinase conformation. As A-loop mutations bias the kinase domain toward the active state, these existing TKI are relatively less active in the setting of TKI resistance mutations seen in GIST. In search of a type I kinase inhibitor that can bind to the kinase domain in its active form, avapritinib (BLU-285) was developed [30] . This compound demonstrates type I binding characteristics, with consequential potent inhibition of KIT and PDGFRA A-loop mutants in vitro and in preclinical models that are superior to existing type II kinase inhibitors. Analogous to imatinib, avapritinib demonstrates a narrow range of kinase selectivity, potently inhibiting KIT and PDGFRA but few other kinases, and is more selective for mutant KIT than its wild-type counterpart. Avapritinib is currently under clinical investigation for advanced GIST (NCT02508532) and other KIT and PDGFRA D842V mutant tumors [80] .
For KIT and many other kinases, activation requires conformational change in the A-loop that moves it away from the ATPand substrate-binding pocket and into contact with a region called the 'switch pocket' or 'switch control', which stabilizes the active kinase conformation [81] . Disruption of this contact with a small molecule leads to destabilization of the active kinase and, unlike traditional TKIs, inhibits the kinase in a non-ATPcompetitive manner (Figure 3 ). Switch pocket inhibitors have shown preclinical promise by inhibiting a variety of TKI-resistant mutations within the BCR-ABL1 kinase [82] . A KIT switch pocket inhibitor, DCC-2618, was developed with the goal of bypassing secondary kinase resistance mutations and has also entered clinical trials for GIST and other tumors (NCT02571036) [84] .
Given the emergence of multiple distinct drug-resistance clones within an individual GIST patient [48, 57] , the concept of combining multiple TKIs targeting a different spectrum of mutations has emerged. Two clinical trials utilizing this approach are under evaluation, either using the commercially available TKIs sunitinib and regorafenib (NCT02164240) or the novel TKI PLX9486 alone or in combination with PLX3397 or sunitinib (NCT02401815). Furthermore, the use of alternating TKIs in the first-line setting as a strategy to prevent the emergence of TKIresistance is under evaluation (NCT02365441). Early results from these trials of novel kinase inhibitors, most notably avapritinib and DCC-2618 [85] , have demonstrated encouraging preliminary evidence of disease control through the targeting of TKI resistance mutations, even in patients treated with multiple prior lines of TKIs.
Novel targeted therapies
Given the propensity of GIST to generate TKI-resistance mutations, targeting alternative steps in the KIT signaling pathway, affecting KIT protein maturation or immune-based therapies, are attractive antineoplastic strategies. Heat shock protein 90 (HSP90) is a protein chaperone that assists in the folding and intracellular transport of RTKs, among many other client proteins. As HSP90 contributes to many oncogenic pathways, the development of HSP90 inhibitors has drawn therapeutic interest in diverse malignancies [86] . HSP90 inhibitors in pre-clinical models have been shown to decrease KIT protein levels, induce cellcycle arrest and apoptosis and decrease xenograft tumor growth [52, 87] . However, early clinical trials to date have shown modest effects in patients with TKI-refractory GIST [88] [89] [90] . As an alternative means of targeting HSP90, histone deacetylase inhibition has been found to lead to HSP90 acetylation and destabilize KIT in vitro [91] , though this strategy has yet to reach clinical trial.
As an alternative means of destabilizing or deactivating KIT protein and enhancing immune response, treatment with KITdirected monoclonal antibodies has been shown to decrease KIT cell-surface expression, enhance macrophage phagocytosis of GIST cells and decrease tumor xenograft growth [92] . A KITdirected antibody is currently in early clinical trials (NCT02642016). The PDGFRA-directed antibody olaratumab has been found to block receptor phosphorylation and downstream signaling through PDGFRA and control xenograft growth [93] and may have effects both on tumor cells and the tumor microenvironment. Olaratumab in combination with doxorubicin has shown a benefit in overall survival in non-GIST soft tissue sarcoma [94] , leading to its approval by the FDA. Considering the dependence upon mutant PDGFRA signaling in a subset of GIST, and expression of PDGFRA in many cases of KIT-mutant GIST, a phase II trial explored the use of olaratumab in GIST [95] . While there was no clear benefit in this study to patients with tumors bearing KIT mutations, of six patients with PDGFRA mutations half experienced prolonged stable disease at a rate higher than expected from historical controls. Additional investigation of olaratumab is warranted, possibly in combination with emerging TKIs, to further evaluate this finding.
KIT and PDGFRA signaling occurs through multiple signal transduction pathways, and inhibitors of these pathways are under clinical development [96] . In preclinical models, PI3K inhibition [97] , AKT inhibition [98] , MEK inhibition [99] and mTOR inhibition [100] have been found to inhibit KIT signaling and show promising effects in vitro and in xenograft models. However, early efforts translating these findings into clinical trials has not succeeded to date [101, 102] , though additional trials are underway with novel agents (NCT01991379, NCT01735968 and NCT01468688). Signaling through fibroblast growth factor receptors (FGFRs) has been found to increase following KIT inhibition in GIST, resulting in drug resistance through alternative and complimentary signal transduction, and FGFR inhibition reduces GIST xenograft tumor growth [103, 104] . Clinical evaluation of FGFR inhibitors is currently underway (NCT02257541). Though there has been substantial preclinical evidence in support of targeting downstream or alternative signaling mediators in GIST, these results have not yet translated into clinical impact. This lack of success to date may have several contributing factors, including compensatory activation of multiple alternative signaling cascades downstream of RTKs, alternative RTK-independent mechanisms of survival in advanced GIST where these novel therapies are initially tested or lack of pairing with an effective TKI.
There has been an evolving understanding of the tumor microenvironment and immune interactions in GIST. Immune cell infiltration into GIST tumors has been well documented, with unique immunologic features seen in localized and metastatic disease and as a consequence of TKI therapy [105, 106] . Imatinib has been found to have important roles in modulating intratumoral T cells to exert an antitumor response, which may in part work by preventing tumor cell production of the immune inhibitory enzyme indoleamine 2,3-dioxygenase (IDO) [107] . Combination treatment with imatinib and checkpoint inhibitors have shown superior effects to imatinib alone in pre-clinical models [107, 108] , though efficacy of checkpoint blockade may depend on concurrent TKI treatment. These findings have broadened interest in studying immunotherapy in many forms for the treatment of GIST [109] . Efforts at utilizing immune checkpoint inhibition alone and in combination with TKI treatment are under early clinical evaluation in GIST (NCT02880020, NCT03291054, NCT02834013 and NCT02500797) [110] .
Discussion Conclusions
From its initial distinction from other sarcomas with similar histology, to the identification of activating KIT mutations and the development of targeted therapies, GIST is an outstanding example of scientific and medical progress in oncology. With prolonged TKI treatment, secondary KIT resistance mutations arise which present challenges to available therapies. Currently, multiple novel kinase inhibitors targeting KIT and PDGFRA resistance mutations through various mechanisms are in clinical trials, with encouraging preliminary results reported. Additional means of therapeutically targeting GIST under clinical investigation include anti-KIT antibodies, modulation of KIT protein maturation or signaling and immune-based therapies. The deep and maturing understanding of this disease, and the development of targeted agents based on its scientific understanding, generates enthusiasm for the future of GIST therapeutics and hope for those currently treating and suffering from this condition.
Funding
None declared.
Disclosure
Dr Heinrich performs consulting for Novartis, Blueprint Medicines, Deciphera Pharmaceuticals, Bayer, MolecularMD and Ariad Pharmaceuticals, provides expert testimony to Novartis and holds equity interest in MolecularMD. Dr Bauer performs consulting for Novartis, Blueprint Medicines, Deciphera Pharmaceuticals, Bayer and has received research funding from Novartis, Incyte and Blueprint Medicines. Dr George performs consulting for and received research funding from Blueprint Medicines and Deciphera Pharmaceuticals and has received research funding from Bayer, Pfizer and Novartis. All remaining authors have declared no conflicts of interest.
A B Figure 3 . Switch pocket inhibition in the ABL1 kinase. (A) Structure of DCC-2036 bound to ABL1 [82] . The TK domain is colored in gold and silver, corresponding to the split kinase domain of KIT, and the A-loop in blue. The ABL1 T315I mutation is labeled in purple, which produces resistance to ATP-competitive inhibitors. (B) Structural overlay of imatinib [83] and DCC-2036 in the ABL1 kinase. DCC-2036 disrupts contact between the A-loop residue R386 and E282 within the switch pocket (expanded view in right panel), favoring the inactive kinase conformation.
